The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A first-in-human study of CRISPR/Cas9-engineered tumor infiltrating lymphocytes (TILs) product GT316 as monotherapy in advanced solid tumors.
 
Jing Guo
No Relationships to Disclose
 
Wei Huang
No Relationships to Disclose
 
Binghui Zhao
No Relationships to Disclose
 
Jing Yu
No Relationships to Disclose
 
Jun Cui
No Relationships to Disclose
 
Jingwei Sun
No Relationships to Disclose
 
Liqing Ma
No Relationships to Disclose
 
Yishan Liu
No Relationships to Disclose
 
Derun Shen
No Relationships to Disclose
 
Lin Shen
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; MSD; SERVIER; Transcenta Holding Limited
Research Funding - BeiGene (Inst)
 
Pin Wang
Stock and Other Ownership Interests - Immune Design Corp.
Consulting or Advisory Role - TCRCure Biopharma Inc.
Patents, Royalties, Other Intellectual Property - A technology for engineering dendritic cells for targeted vaccination. A series of patents was awarded to California Institute of Technology and University of Southern California. Immune Design Corp. has licensed these patents, in which certain royalties
 
Yarong Liu
No Relationships to Disclose
 
Zhongping Cheng
No Relationships to Disclose